Methylation status of EXT1 and EXT2 promoters and two mutations of EXT2 in chondrosarcoma

Area of Science:

• Oncology
• Genetics
• Epigenetics

Background:

• Germline mutations in EXT1 or EXT2 are associated with multiple osteochondromas and chondrosarcoma development.
• Mutations in EXT1/EXT2 are rare in secondary chondrosarcomas from osteochondroma, which often show loss of heterozygosity.
• Primary chondrosarcomas typically do not exhibit loss of heterozygosity at EXT1/EXT2 loci.

Purpose of the Study:

• To investigate promoter methylation of EXT1 and EXT2 in chondrosarcomas.
• To analyze mutations in the coding regions of EXT1 and EXT2 in chondrosarcoma cases.
• To understand the role of EXT gene family members in primary chondrosarcoma development.

Main Methods:

• Methylation-specific polymerase chain reaction (PCR) was used to assess promoter methylation of EXT1 and EXT2.
• PCR-single-strand conformation polymorphism and sequencing analysis were employed for mutation detection in EXT1 and EXT2 coding regions.
• Analysis was conducted on 20 chondrosarcoma cases and five cell lines.

Main Results:

• No promoter methylation of EXT1 or EXT2 was detected in any of the analyzed chondrosarcoma cases.
• Both EXT1 and EXT2 genes were expressed in all tested cell lines.
• Two missense mutations in EXT2 (D227E and R299H) were identified in chondrosarcoma cases.

Conclusions:

• Promoter methylation is not a primary mechanism for EXT1/EXT2 silencing in chondrosarcomas.
• Mutations in EXT2 should be considered in the development of primary chondrosarcomas.
• Further investigation into the EXT gene family's role is warranted for understanding tumor development.